Voyager Therapeutics (VYGR) Other financing activities (2018 - 2025)

Voyager Therapeutics has disclosed Other financing activities across 8 years of filings, most recently posting $434000.0 for Q2 2025.

• Other financing activities for Q2 2025 came in at $434000.0, down 32.08% year-over-year; the trailing twelve-month figure through Jun 2025 was $1.8 million (down 7.49% YoY), and the FY2025 annual result was $549000.0, down 53.16% from the prior year.
• Other financing activities came in at $434000.0 for Q2 2025 at Voyager Therapeutics, down from $639000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $639000.0 in Q2 2024 to a low of $313000.0 in Q2 2022.
• The 5-year median for Other financing activities is $434000.0 (2025), against an average of $476800.0.
• Across the five-year window, Other financing activities slumped 46.03% in 2022 and surged 52.87% in 2024, its largest moves.
• Voyager Therapeutics' Other financing activities stood at $580000.0 in 2021, then plunged by 46.03% to $313000.0 in 2022, then jumped by 33.55% to $418000.0 in 2023, then jumped by 52.87% to $639000.0 in 2024, then sank by 32.08% to $434000.0 in 2025.
• The last three Other financing activities figures came in at $434000.0 (Q2 2025), $639000.0 (Q2 2024), and $418000.0 (Q2 2023), per Business Quant data.